Reperfusion Treatment in Acute Pulmonary Embolism
Reperfusion Treatment in Acute Pulmonary Embolism: A Multicenter Observational Study in the Nordic Countries
Sahlgrenska University Hospital
220 participants
Apr 1, 2025
OBSERVATIONAL
Conditions
Summary
International guidelines recommend immediate reperfusion with systemic thrombolysis (ST) as first-line treatment in high-risk pulmonary embolism (PE). The therapy improves hemodynamics and overall survival but is also associated with a significant risk of severe bleeding. Catheter-directed intervention (CDI) is recommended as an alternative reperfusion therapy in high-risk PE when ST is contraindicated or has failed, as well as in patients who deteriorate or fail to improve during anticoagulation (AC) treatment. Despite lack of high-quality evidence and randomized studies between CDI and standard care, the use of CDI is spreading rapidly in high-risk PE and in less severe PE not fulfilling current treatment criteria.
Eligibility
Inclusion Criteria2
- All adult patients (≥18 years), including pregnant women, with verified (CTPA, angiography or scintigraphy) acute pulmonary embolism who are planned for, or have received, treatment with catheter directed intervention or systemic thrombolysis
- Informed consent (for patients who do not survive before informed consent can be obtained, a waiver of consent applies)
Exclusion Criteria2
- Ongoing enrolment in interventional catheter directed intervention trial
- Surgical embolectomy as primary reperfusion treatment
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Catheter directed intervention for treatment of pulmonary embolism
Systemic thrombolysis
Locations(13)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07003646